• Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza
• Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis

NEW YORK and SUZHOU, China, May 18, 2026 — Accro Bioscience Inc. (“Accro Bioscience”), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases, announced the closing of its $50 million Series C financing. The round was led by OrbiMed, with participation from TCG Crossover (“TCGX”), LAV, Cenova Capital, and existing investors Shenzhen Capital Group (“SCGC”) and Oriza Holdings (“Oriza”).

Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&I diseases.

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, said: “We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases. I’m grateful to our investors who share our vision and have supported us continuously.”

Steven Wang, Ph.D., CFA, Partner at OrbiMed, said: “We are highly impressed by Accro Bioscience’s innovative pipeline. The team’s scientific acumen and track record of strong execution were instrumental in our decision to invest. OrbiMed is excited to partner with Accro to accelerate their global clinical development.”

About AC-101

AC-101 is a novel, selective RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro Bioscience’s proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance from U.S. FDA for a Phase II clinical trial.

About Accro Bioscience

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company’s robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies.

For more information, please visit www.accropeutics.com.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

For more information, please visit www.orbimed.com.

SOURCE Accro Bioscience Inc.

SUZHOU, China and GEMBLOUX, Belgium, May 18, 2026 — Full-Life Technologies (“Full-Life“, the “Company“), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life’s strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, as well as other renowned shareholders.

Proceeds from the Series D round will be used to advance the Company’s clinical stage assets, including potential best-in-class [225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programs, all of which emerged from its UniRDC™ discovery platform. Proceeds will also facilitate the initiation of GMP-grade 225Ac manufacturing at the Company’s state-of-the-art facility in Belgium. Having isotope supply and manufacture under its complete control is a significant strategic advantage in advancing radiotherapeutics rapidly through clinical development.

“Full-Life is distinguished not only by their scientific vision, but their ability to translate it into tangible clinical and operational milestones at a global scale,” said Hao Dong, Managing Director at Vivo Capital. “We are impressed by their early discovery efficiency, the strong emerging data from their lead program, and the accelerated progress of their manufacturing facility in Belgium. Leading this Series D financing reflects our conviction that Full-Life is transitioning from a platform innovator to a fully integrated radiopharmaceutical company, and we are excited to support their next phase of value creation.”  

“This financing reflects the significant value we have created over the past four years, evolving from a platform builder to a clinical-stage company,” said Julie Wu, President and Chief Financial Officer of Full-Life. “With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply.”

With completion of this round, Full-Life has secured nearly US$350 million funding since its inception in 2021, including equity financing and debt financing.

About Vivo Capital

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a multi-strategy platform spanning venture capital, private equity, and public markets. The firm manages over $7.0 billion across 16 USD and RMB funds and has invested in over 460 companies worldwide. Vivo Capital focuses exclusively on the healthcare sector, including biotechnology, pharmaceuticals, medical devices, and pharma services, with an emphasis on the world’s largest and fastest-growing markets. The firm is differentiated by its “Ecosystem Strategy,” leveraging deep industry networks and operational capabilities to deliver strategic support beyond capital. Headquartered in Palo Alto, California, Vivo Capital has offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore, supported by a global team of over 70 professionals.

About Full-Life Technologies

Full-Life Technologies (“Full-Life”) is a privately held, fully-integrated clinical-stage global radiotherapeutics company with operations worldwide. Our mission is to deliver the power of radiotherapy to cancer patients worldwide by owning the entire value chain for radiopharmaceutical research & development including production & commercialization. By combining advanced manufacturing capabilities, biological insights and clinical efficiency, the Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences and unwavering dedication to patients worldwide. Learn more at: https://www.full-life.com/  

SOURCE Full-Life Technologies

NORWALK, Conn., May 18, 2026 — Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics’ $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures.

Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company’s proprietary CONNECT platform is designed to identify therapeutically actionable signaling pathways that drive neuroinflammation, neurodegeneration, and synaptic loss.

Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer’s disease and other neurodegenerative conditions, and Violet’s lead program is designed to address this core pathology through glial-mediated synaptic preservation and repair. “Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle,” said Altar Munis, Associate at Lifespan Vision Ventures. “The company’s CONNECT platform gives it a systematic way to uncover how glial signaling contributes to synaptic dysfunction, with EphB3 representing a strong first step toward therapies that may protect brain health across aging and neurodegenerative disease.”

“We are pleased to welcome LVV as the lead investor in this extension round. LVV brings deep sector expertise in technologies that will impact diseases of aging and cognition. Likewise, their addition to the board adds valuable perspective as we continue to advance our EphB3 program towards the clinic and to develop our CONNECT discovery platform,” said Meredith Fisher, Partner at Mass General Brigham Ventures and CEO of Violet.

Proceeds from the financing will support advancement of Violet’s lead small molecule program targeting EphB3 through key IND-enabling activities. EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte signaling, emerged directly from Violet’s CONNECT platform and represents the company’s first therapeutic target generated from its cellular connectome approach.

About Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan.

Contact: [email protected]

About Violet Therapeutics
Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company’s proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.

For more information, visit www.violettx.com

Media contact:
Meredith Fisher, CEO
[email protected]

SOURCE LifeSpan Vision Ventures

HONG KONG, May 18, 2026 — AEON, the settlement layer built for the agentic economy, today announced it has successfully closed an $8 million pre-seed funding round. The round was led by YZi Labs, with participation from a robust group of leading investors, including IDG Capital, HashKey Capital, Stanford Blockchain Builders Fund, Oak Grove Ventures, SevenX Ventures, Alchemy Ventures, Draper Dragon, Contribution Capital, and Uphonest Capital.

The funding will accelerate AEON’s mission to build the financial backbone required for a new economic paradigm, where AI reshapes production relations across the internet and becomes an active participant in global commerce. AEON is building the settlement layer that this new paradigm demands, powering the agentic economy at scale, and bridging Agent-to-Agent (A2A) interactions with real-world merchant settlement.

As one of the earliest official partners of Coinbase‘s x402 protocol, AEON has been at the forefront of turning the concept of AI payments into reality. The company launched its first AI payment product in May, enabling AI agents to execute on-chain transactions and connect to over 50 million real-world merchants across the globe. With AEON, AI enters the marketplace, where ideas, intent, and intelligence can directly move value.

In partnership with BNB Chain, AEON recently launched the x402 Facilitator, built natively on the BNB Chain infrastructure. This enables verifiable transactions, on-chain settlement, and immutable receipts for millions of service providers within the BNB ecosystem, building payment infrastructure constructed for the agentic economy at internet scale.

By leveraging AI native protocols like x402, ERC-8004, Google AP2, and MCP, AEON enables autonomous and verifiable AI agent transactions that bridge the gap between digital agent interactions and real-world settlement. Its Protocol Kernel x402 Stack encapsulates payment instructions into HTTP 402 status codes, embeds settlement logic directly into every API request or service subscription, and ensures real-time clearing between A2A transactions. The distributed Trust Hub verifies transaction payloads with atomic finality, guaranteeing irreversible settlement. This architecture enables continuous value flows between agents, and through AEON’s Physical Gateway, extends into Agent-to-Merchant scenarios where agents can pay.

Building in phases, AEON’s roadmap begins with a completed foundation of cross-chain infrastructure and payment standards. It is now advancing into trust and scale, evolving from payment verification to execution verification while expanding its global settlement network across emerging markets and traditional financial rails. Looking ahead, AEON aims to unlock fully autonomous agent collaboration supported by a native KYA credit system and with full-stack AI financial services, where AI agents can coordinate, transact, and settle value across complex real-world scenarios. 

AEON’s founding team brings deep experience from Binance, Chainlink, Google, HSBC, and GrabPay, combining with deep expertise in AI, blockchain architecture, and real-world payments. This blend allows AEON to build a settlement layer the way the agentic economy actually operates, scaling payments that are verifiable, trustless, and at machine speed.

“AEON is not just bridging AI and real-world commerce, we are building the settlement layer the agentic economy inherently requires,” said Eddie Li, CEO and co-founder of AEON. “As production relations shift toward an economy powered by autonomous agents and value exchange between AIs, we believe a settlement layer built for the agentic economy will emerge and this economic paradigm needs its own financial foundation. This funding empowers us to accelerate that mission, advancing our settlement layer built for AI, and deepening collaboration with ecosystem partners like Coinbase and BNB Chain.”

About AEON

AEON is the settlement layer built for the agentic economy, leveraging leading protocols to enable autonomous, verifiable AI agent transactions at scale. It bridges Agent-to-Agent (A2A) interactions with real-world settlement and continuous value flows.

Serving more than 2 million users and processing 30M monthly transactions, AEON is backed by YZi Labs and IDG Capital, with participation from investors including HashKey Capital, Stanford Blockchain Builders Fund, etc.

Website | X | Telegram | Medium | AEON Pay

About YZi Labs

YZi Labs manages over $10 billion in assets globally. Our investment philosophy emphasizes impact first—we believe that meaningful returns will naturally follow. We invest in ventures at every stage, prioritizing those with solid fundamentals in Web3, AI, and biotech.

YZi Labs’ portfolio covers over 300 projects from over 25 countries across six continents. Some notable portfolios include Trustwallet, CoinMarketCap, Polygon, Injective, Ethena, Safepal Wallet, Better Payment Network, Aster, XAI (acquired by SpaceX), and more. More than 65 of YZi Labs’ portfolio companies have gone through our incubation program, EASY Residency. For more information, follow YZi Labs on X. 

SOURCE AEON

Financing and expanded board leadership position the company to accelerate FDA clearance and commercialization of its novel imaging system

SUNNYVALE, Calif. and GIVATAYIM, Israel, May 18, 2026 — Vortex Imaging Inc. announced today the closing of a $12 million financing round, supported by existing and new investors, including 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, and PhiFund Ventures.

The financing will support the continued development, regulatory clearance, and market launch of Vortex Imaging’s computational ultrasound system, a novel imaging technology designed to enable high-quality 3D volumetric imaging at the point of care using pioneering computational image reconstruction technology, utilizing GPUs-on-Cloud.

Today, many advanced imaging workflows rely on centralized radiology suites, which can contribute to delays in access to imaging and patient care. Vortex Imaging is developing a compact ultrasound-based imaging system designed to bring advanced 3D volumetric imaging into everyday clinical settings. The system aims to reduce variability associated with conventional ultrasound workflows by enabling standardized, reproducible volumetric datasets with a reduced learning curve, while avoiding ionizing radiation and large imaging infrastructure.

The reconstructed images are intended to provide physicians with advanced 3D volumetric visualization capabilities in a format traditionally associated with CT and MRI, while maintaining the accessibility, safety, and portability advantages of ultrasound.

“This financing round marks a major milestone for Vortex Imaging,” said Tomer Ben David, CEO of Vortex Imaging. “Vortex is focused on transforming ultrasound from a highly operator-dependent modality into a standardized, volumetric imaging system capable of delivering advanced 3D clinical insights directly at the point of care. We are excited to have the support of experienced investors and board members as we continue advancing toward FDA clearance and initial clinical deployment.”

In addition, Ori Hadomi, former CEO of Mazor Robotics and current Vice President of Strategic Initiatives & Partnerships at Medtronic, has been appointed Chairman of the Board, bringing significant experience in guiding transformative medical technologies from development to global commercialization.

The board will also include experienced healthcare and medtech leaders, including Chris Cleary, former Vice President of Corporate Development at Medtronic and former GE Healthcare executive; Yahal Zilka, co-founder and Managing Partner at 10D Ventures; and Dr. Yael Grunbaum, Partner at Entree Capital and Head of Entrée Bio.

Together, the expanded board brings deep expertise across medical imaging, strategic growth, corporate development, and commercialization of global medtech platforms.

Vortex Imaging’s initial clinical focus is on urology and nephrology, with broader future applications planned across additional diagnostic and procedural domains.

“Vortex Imaging has the potential to significantly expand how and where advanced imaging is performed,” said Ori Hadomi, Chairman of the Board. “The combination of high-quality volumetric imaging, reduced operator dependency, and a compact ultrasound-based platform could enable a far more scalable and standardized approach to imaging across healthcare systems.”

For more information visit: https://www.vortex-imaging.com/ or LinkedIn.

Watch: Why wait for imaging? 

Contact:
Izik Ithakov
[email protected]

SOURCE Vortex Imaging Inc.

GERMANTOWN, Wis., May 18, 2026 — Innovative Motion Technologies (IMT), a global industrial technology platform and Cathay Capital portfolio company, today announced the successful closing of a new senior credit facility led by TPG Twin Brook. The financing supports IMT’s continued growth and buy-and-build strategy across diversified end markets including healthcare, industrial, HVAC, and utilities.

The new financing strengthens the company’s capital structure and provides additional flexibility to invest in its vertically integrated platform, expand engineering capabilities, pursue strategic and synergistic acquisitions, and broaden its product offering across key end markets, including healthcare, industrial, HVAC, and utilities. The financing was led by TPG Twin Brook, which served as sole lender.

“This financing enables us to continue investing in the business while expanding our product offering across both existing and new end markets,” said Rich Weeden, CEO of IMT. “We remain focused on building on our platform, supporting customers across our diversified end markets, and driving continued growth across the business.”

Andrew Hartinger, CFO of IMT, added “We are pleased to have completed this financing with a top-tier lending partner, which provides significant capacity to execute IMT’s buy-and-build strategy.”

“Since our investment in IMT, the Company has evolved into a differentiated global platform in interface and control technologies, supported by best-in-class engineering and a scaled, diversified footprint across attractive end markets,” said Mark Woods, Partner at Cathay Capital. “This financing enhances IMT’s ability to accelerate growth and deliver on its long-term value creation strategy.”

Piper Sandler served as sole debt placement agent on the transaction.

About Innovative Motion Technologies

Innovative Motion Technologies (IMT) is a global industrial technology platform and industry-leading designer and supplier of advanced motion control and interface solutions across a diversified set of OEM and aftermarket applications. The Company operates through a family of brands to deliver highly engineered products across multiple end markets worldwide. For more information, please visit https://imtbrands.com.

About Cathay Capital

Cathay Capital is a global private equity and venture capital investment firm supporting healthcare, technology and consumer companies throughout North America, Europe, and Asia. The firm helps middle-market companies and startups navigate opportunities for growth, international expansion, and sustainable transformation. Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its platform connects people with global reach and local expertise – from investors and entrepreneurs to management teams and leading corporations – to share knowledge, the tools to scale and to transform businesses.

Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $5.5 billion in assets. It has made over 250 investments in verticals including healthcare, technology, and consumer from offices in New York, San Francisco, Paris, Munich, Berlin, Madrid, Shanghai, Beijing, Shenzhen, and Singapore.

For more information, visit: www.cathaycapital.com.

Media Contact:
Mary Magnani, CodePR
[email protected]

SOURCE Cathay Capital

NEW YORK, May 18, 2026 — Searchable, the AI performance marketing platform helping businesses compete in AI-driven search, has raised $14 million in funding led by global venture capital firm Headline. The latest round of funding values the company at $85 million, reflecting investor confidence that AI-led search will be one of the most important customer acquisition channels of the next decade. 

The funding follows a period of rapid growth, including reaching $2 million in revenue in 4.5 months and onboarding nearly 1000 customers.

Headline, whose portfolio includes Bumble, Farfetch, Goop and Sonos, has a track record of backing global category leaders, including Semrush, the SEO software group acquired by Adobe in a $1.9bn deal. Its investment comes as CMOs confront what many see as the biggest change in online visibility since the early days of Google.

With fresh capital from Headline, Searchable plans to accelerate product development across its execution engine and expand its presence in both the US and UK markets.

Dominic R. Wilhelm, Partner at Headline, said:

“AI–driven discovery is rewriting how customers find products. As more searches are answered directly by AI, brands that are invisible in this layer of search will see less demand. The companies that adapt first will grow market share; those that don’t will lose it quietly.”

Wilhelm adds: “We see Searchable becoming part of the core infrastructure for this shift, not just reporting on what AI engines say about a brand, but directly improving the visibility and revenue outcomes that matter to management teams and boards.”

AI-enabled search is projected to reach roughly 70 percent penetration by 2027, while 65 percent of searches already end without a click. AI-generated overviews now appear in nearly half of Google searches, reshaping how consumers discover products and services.

Chris Donnelly, founder of Searchable, said: “Search is going through a once–in–a–generation reset. When an AI assistant recommends your brand, customers arrive with more trust and a shorter path to purchase. Based on our own data customers are converting at 3x higher when they arrive from ChatGPT and other LLMs. If you aren’t visible in those answers, you’re giving ground to competitors every day.”

Over the next 12 to 24 months, the company expects three structural shifts: the automation of repetitive manual SEO labour through agentic systems; the rise of AI commerce as a standalone optimisation layer; and the convergence of paid and organic AI visibility into unified attribution models.

British serial entrepreneur Donnelly, who sold SEO agency Verb for $25 million and scaled Lottie Org to a nine-figure valuation, explains: “For more than a decade, SEO has been labour–intensive and expensive. Over the next two years, a large share of that work becomes automatable. Our goal is to give companies an execution layer for AI search that cuts SEO costs by up to 40 percent while growing high–intent traffic.”

Searchable works with brands including American Express, KPMG and Siemens. On average, enterprise-scale customers report a 22 percent increase in AI-driven traffic within their first 60 days of using the platform. The US-based company is incorporated in Delaware and operates between New York and London.

About Searchable
Founded in 2025 by British serial entrepreneur Chris Donnelly, Searchable is a new AI performance platform that helps brands understand, track and improve how they appear across AI-led search. Acting as a growth command centre, it tracks visibility on 10 AI engines, surfaces insights through interactive agents, connects analytics from Google Analytics & Search Console, and turns data into actions that drive traffic growth. The US-based company is incorporated in Delaware and operates between New York and London, and is redefining performance marketing for the age of AI.

For further information see: https://www.searchable.com/

Photo – https://mma.prnewswire.com/media/2982026/Chris_Donnelly_Founder_of_Searchable.jpg
Logo – https://mma.prnewswire.com/media/2982025/Searchable_Logo.jpg

SOURCE Searchable

Medical devices are increasingly defined by software, with value moving from hardware to real-world data and AI-driven intelligence delivering guidance and interpretation

NEW YORK, May 18, 2026 — Aegis Ventures, a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies, today released a new whitepaper, Medical Devices in the AI Era, examining why medical devices have historically underperformed in venture portfolios, and why the next decade is likely to look different.

Medical devices have produced some of the most important companies in healthcare, yet sparse venture-scale outcomes. Over the past two decades, very few venture-backed medical device companies have exited above $1 billion, with most requiring long, capital-intensive development cycles of more than ten years from founding to exit.

Even as healthcare’s share of U.S. venture capital has grown from ~21% to over 32% since 2018, medical devices have remained flat at 2–3% of overall investment. The new Aegis whitepaper posits that the conditions which produced this gap are beginning to shift.

“The next era of medtech will be defined by platforms that combine sensing technologies, AI, and real-world data to generate clinically meaningful insights over time,” said John Beadle, Co-Founder and Managing Partner of Aegis Ventures. “As these structural shifts converge, we believe medical devices can evolve into platforms that expand across clinical applications, make specialist-level insight accessible in more care settings, and generate proprietary data that improves performance and creates advantages that become increasingly difficult to replicate. While AI does not reduce all of the barriers that make medtech challenging to build, for companies that get it right, it can meaningfully raise the ceiling for both impact and scale, enabling a new generation of medtech companies to support a more intelligent, proactive model of medicine.”

The Aegis whitepaper identifies three AI-driven structural shifts already reshaping the medical device category:

1. expanding total addressable markets, such as a single sensing platform supporting multiple clinical applications
2. tapping into higher-value clinical workflows, such as AI-guided systems that allow generalists to perform tasks previously reserved for specialists
3. building compounding data advantages, with devices that create proprietary datasets tied to real-world usage and outcomes

Taken together, these shifts suggest that while the category remains difficult to build in, the ceiling for outcomes is rising meaningfully, with the potential to generate larger venture-scale companies than the category has historically produced.

Aegis points to its own portfolio companies as examples of these shifts.

Optain Health has built an AI-powered retinal imaging platform to enable primary care providers to identify eye and cardiovascular diseases earlier than the traditional specialist referral pathway typically allows. While currently deployed for diabetic retinopathy screening, there is promising potential to expand Optain’s clinical utility to assess additional types of disease by developing new algorithms, while using the same hardware.

Wavelet Medical, another Aegis portfolio company, uses AI to non-invasively capture and reconstruct EEG signals through the mother’s abdomen to identify signs of fetal distress in real-time. The platform leverages sensors, data, and AI in service of reducing brain injury at birth and unnecessary C-sections.

The Aegis whitepaper Medical Devices in the AI Era is available now at https://aegisventures.com/insights/medical-devices-in-the-ai-era

About Aegis Ventures

Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. The Aegis platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals who are driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on artificial intelligence and health technology. Within these verticals, Aegis seeks to create companies that use technology to transform healthcare quality, access, and cost, focusing on innovations that promote seamless continuity of care, patient empowerment, and better-informed clinical decision-making. In parallel with launching our first six successful portfolio companies over the last several years, Aegis has created the Digital Consortium, a group of fourteen leading health systems that will partner with Aegis to co-develop, invest in, and launch new companies. To learn more about Aegis, visit our website and follow us on LinkedIn.

Media Contact:
Kara Spak
[email protected]

SOURCE Aegis Venture Partners LLC

BOSTON, May 18, 2026 — Tomorrow.io, the world’s leading Resilience Platform™, today announced an additional $35 million investment from existing partner Pitango, and their partner Harel Insurance, joining Stonecourt Capital and HarbourVest Partners, bringing the company’s previously announced Series F to $210 million. The expanded investment reflects a multi-year partnership and deepening conviction in Tomorrow.io’s role as critical AI weather intelligence infrastructure for organizations operating in an increasingly volatile world.

The extension follows Tomorrow.io’s $175 million Series F earlier this year, which supported the planned deployment of DeepSky—the world’s first AI-native weather satellite constellation—alongside broader investments in its space infrastructure and the advancement of its AI-driven platform. The additional capital will further accelerate AI capabilities, expand the company’s space-based observation network, and advance development of its agentic platform to deliver real-time, actionable resilience intelligence at a global scale.

Weather-driven disruption is increasingly impacting day-to-day operations across industries, raising the stakes of how organizations plan, respond, and allocate resources. At the same time, as AI adoption moves from experimentation to scaled deployment, the need for proprietary, high-quality data has become foundational. Against this backdrop, Tomorrow.io’s combination of space-based observation, advanced weather modeling, and generative AI is transforming weather intelligence into mission-critical infrastructure for the modern enterprise.

“Our continued investment in Tomorrow.io reflects what we believe defines truly category-shaping companies: visionary founders, a long-term mission, and a partnership that compounds over time. This team isn’t simply building a product: they’re laying down critical infrastructure for how the world adapts to volatility. We’re proud to keep building alongside them,” said Aaron Mankovski, Managing Partner at Pitango.

“Weather is one of the most powerful forces shaping the global economy, yet it remains one of the least fully integrated into how decisions are made,” said Shimon Elkabetz, CEO and Co-Founder of Tomorrow.io. “Tomorrow.io was built to change that by transforming how the planet is observed and turning data into real-time, actionable intelligence. As AI becomes embedded in operations, that capability becomes foundational. With Pitango’s continued partnership, we are accelerating Tomorrow.io into the infrastructure layer organizations depend on every day.”

Together, Tomorrow.io and Pitango remain focused on building the AI-based foundational layer for resilience in the global economy, helping the world’s largest organizations adapt, decide, and act in real time as weather, supply chains, and operating environments grow more volatile.

About Tomorrow.io

Selected as a TIME 100 Most Influential Company and a Fast Company Most Innovative Company, Tomorrow.io is the world’s leading Resilience Platform™. With a fully operational proprietary satellite constellation and a generative AI–integrated forecasting engine, Tomorrow.io delivers the world’s most accurate and actionable weather intelligence. Combining next-generation space technology, advanced AI, and proprietary weather modeling, the platform empowers organizations to proactively manage risk, seize opportunity, and improve operational efficiency. Trusted by six of the top ten Fortune 500 companies, Tomorrow.io serves as essential infrastructure for the global economy, enabling industries from aviation and energy to logistics and government to adapt in real time to an increasingly volatile world.

About Pitango

Pitango is Israel’s largest and longest standing venture capital fund. We have raised 13 funds to date that amount to $3+ billion in assets, and invested in over 300 companies including Via, AppsFlyer, Finout, DriveNets, AI21 Labs, QuantHealth and Protai. We have overseen 91 exits and IPOs, including Taboola, Riskified, Vertos, and Forescout. Our firm operates through three dedicated funds: Pitango First, Pitango Growth, and Pitango HealthTech.

MEDIA CONTACT 
Tomorrow.io
[email protected]

SOURCE Tomorrow.io